Literature DB >> 11731802

Altered responsiveness to cocaine in rats exposed to methylphenidate during development.

Susan L Andersen1, Andreas Arvanitogiannis, Andrea M Pliakas, Celeste LeBlanc, William A Carlezon.   

Abstract

Evidence in laboratory animals indicates that exposure to stimulants produces sensitization to their rewarding effects, a process that in humans would be expected to increase the risk of substance abuse. However, therapeutic administration of stimulants such as methylphenidate (MPH) in children with attention deficit hyperactivity disorder reportedly reduces the risk of substance abuse. Here we show in rats that exposure to MPH during pre-adolescence causes behavioral and neurobiological adaptations that endure into adulthood, and that are consistent with increased sensitivity to the aversive effects of cocaine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11731802     DOI: 10.1038/nn777

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  85 in total

1.  A silent synapse-based mechanism for cocaine-induced locomotor sensitization.

Authors:  Travis E Brown; Brian R Lee; Ping Mu; Deveroux Ferguson; David Dietz; Yoshinori N Ohnishi; Ying Lin; Anna Suska; Masago Ishikawa; Yanhua H Huang; Haowei Shen; Peter W Kalivas; Barbara A Sorg; R Suzanne Zukin; Eric J Nestler; Yan Dong; Oliver M Schlüter
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  Chronic psychostimulant exposure to adult, but not periadolescent rats reduces subsequent morphine antinociception.

Authors:  Michelle C Cyr; Susan L Ingram; Sue A Aicher; Michael M Morgan
Journal:  Pharmacol Biochem Behav       Date:  2012-03-03       Impact factor: 3.533

3.  Preventative treatment in an animal model of ADHD: Behavioral and biochemical effects of methylphenidate and its interactions with ovarian hormones in female rats.

Authors:  Jodi L Lukkes; Nadja Freund; Britta S Thompson; Shirisha Meda; Susan L Andersen
Journal:  Eur Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 4.600

Review 4.  Neurobehavioral changes arising from early life dopamine signaling perturbations.

Authors:  Lorena B Areal; Randy D Blakely
Journal:  Neurochem Int       Date:  2020-04-20       Impact factor: 3.921

5.  Dopamine and serotonin signaling during two sensitive developmental periods differentially impact adult aggressive and affective behaviors in mice.

Authors:  Q Yu; C M Teixeira; D Mahadevia; Y Huang; D Balsam; J J Mann; J A Gingrich; M S Ansorge
Journal:  Mol Psychiatry       Date:  2014-03-04       Impact factor: 15.992

6.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.

Authors:  Bing Gong; Ottavio V Vitolo; Fabrizio Trinchese; Shumin Liu; Michael Shelanski; Ottavio Arancio
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

7.  Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine.

Authors:  Megan J Shram; Douglas Funk; Zhaoxia Li; Anh D Lê
Journal:  Psychopharmacology (Berl)       Date:  2006-04-04       Impact factor: 4.530

Review 8.  Methylphenidate and the juvenile brain: enhancement of attention at the expense of cortical plasticity?

Authors:  Kimberly R Urban; Wen-Jun Gao
Journal:  Med Hypotheses       Date:  2013-09-17       Impact factor: 1.538

9.  Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine.

Authors:  Ronald Kuczenski; David S Segal
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

10.  Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood.

Authors:  Salvatore Mannuzza; Rachel G Klein; Nhan L Truong; John L Moulton; Erica R Roizen; Kathryn H Howell; Francisco X Castellanos
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.